KIT and acute myeloid leukemia: As a novel type I tyrosine kinase inhibitor, avapritinib potently targets both wild-type and mutant forms of KIT (exon11/17) and PDGFRA.Here, we report two pediatric SM with AML1::ETO+ AML patients induced by novel KIT exon11 mutations not previously documented in medical literature.